Oncolytic virotherapy in hepato ‐bilio‐pancreatic cancer: The key to breaking the log jam?

In this work, we systematically review and summarize the current status of treatment and the application of oncolytic viruses for HCC, pancreatic cancer, and biliary tract cancer. Most OV therapies exhibits potent, specific oncolysis both in cell lines in vitro and the animal models in vivo and in patients. What's more, we conclude the improvement strategy for next generation of oncolytic viruses therapies. AbstractTraditional therapies have limited efficacy in hepatocellular carcinoma, pancreatic cancer, and biliary tract cancer, especially for advanced and refractory cancers. Through a deeper understanding of antitumor immunity and the tumor microenvironment, novel immunotherapies are becoming available for cancer treatment. Oncolytic virus (OV) therapy is an emerging type of immunotherapy that has demonstrated effective antitumor efficacy in many preclinical studies and clinical studies. Thus, it may represent a potential feasible treatment for hard to treat gastrointestinal (GI) tumors. Here, we summarize the research progress of OV therapy for the treatment of hepato ‐bilio‐pancreatic cancers. In general, most OV therapies exhibits potent, specific oncolysis both in cell lines in vitro and the animal models in vivo. Currently, several clinical trials have suggested that OV therapy may also be effective in patients with refractory hepato‐bilio‐pancreatic cancer. Multiple strategies such as introducing immunostimulatory genes, modifying virus capsid and combining v...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research